Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer - PubMed
5 days ago
- #Neoadjuvant Therapy
- #Immunotherapy
- #Breast Cancer
- Neoadjuvant therapy combining aromatase inhibitors (AIs) and durvalumab was evaluated in postmenopausal patients with HR+/HER2-negative breast cancer.
- The study aimed to enhance the efficacy of neoadjuvant endocrine therapy by adding immunotherapy (durvalumab).
- The primary endpoint was achieving a modified Preoperative Endocrine Prognostic Index (mPEPI) score of 0.
- 17 patients received durvalumab every 4 weeks plus daily AI for 6 months before surgery.
- Treatment was well-tolerated, with most adverse events being grade 1-2.
- 58.8% of patients showed a clinical complete response, but no pathologic complete responses occurred.
- Only 3 patients (17.6%) achieved mPEPI 0, which did not meet the criteria to proceed to the second stage of the study.
- The combination was safe but showed limited pathologic efficacy in an unselected HR+/HER2-negative population.
- Favorable long-term outcomes suggest further investigation in biomarker-selected subgroups.